Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bucindolol - ARCA biopharma Inc

Drug Profile

Bucindolol - ARCA biopharma Inc

Alternative Names: BMY 13105; Bucindolol hydrochloride; Gencaro; MJ 13105; MJ 131051

Latest Information Update: 06 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer ARCA biopharma Inc; Medtronic
  • Class Anti-ischaemics; Antiarrhythmics; Heart failure therapies; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Beta 2 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Atrial fibrillation
  • Discontinued Heart failure; Myocardial infarction

Most Recent Events

  • 18 Feb 2020 ARCA Biopharma anticipates to initiate the phase III PRECISION-AF trial for Atrial fibrillation (Prevention, Recurrent) in the fourth quarter of 2020
  • 06 Jan 2020 Phase-II/III development is ongoing for Atrial fibrillation in Bulgaria, Canada, Hungary, Netherlands, Poland, Serbia, USA (ARCA biopharma Inc website, January 2020)
  • 31 Jul 2019 The US FDA approves amendment to Special Protocol Assessment agreement for the phase III PRECISION-AF trial in Atrial fibrillation
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top